![[img]](https://epub.uni-regensburg.de/style/images/fileicons/application_pdf.png) | Lizenz: Creative Commons Namensnennung 4.0 International PDF - Veröffentlichte Version (1MB) |
- URN zum Zitieren dieses Dokuments:
- urn:nbn:de:bvb:355-epub-777137
- DOI zum Zitieren dieses Dokuments:
- 10.5283/epub.77713
Ramanan, Athimalaipet V. ; Dick, Andrew D. ; Jaki, Thomas 
; Caruso, Gianmarco ; Robertson, David S. ; Jones, Ashley P. ; Hardwick, Ben ; Drake, Sian ; Balasubramaniam, Balini ; Ciurtin, Coziana ; Foeldvari, Ivan ; Kreps, Elke O. ; Leahy, Alice ; May, Kristina ; Quartier, Pierre ; Robert, Matthieu P. ; Simonini, Gabriele ; Guly, Catherine ; Beresford, Michael W.
; Caruso, Gianmarco ; Robertson, David S. ; Jones, Ashley P. ; Hardwick, Ben ; Drake, Sian ; Balasubramaniam, Balini ; Ciurtin, Coziana ; Foeldvari, Ivan ; Kreps, Elke O. ; Leahy, Alice ; May, Kristina ; Quartier, Pierre ; Robert, Matthieu P. ; Simonini, Gabriele ; Guly, Catherine ; Beresford, Michael W. Zusammenfassung
Background: Juvenile idiopathic arthritis (JIA)-associated uveitis and chronic anterior uveitis in children may result in permanent sight loss. Currently, the only licensed and approved treatment for JIA-uveitis is adalimumab. However, even in patients where adalimumab may be initially effective, therapeutic response may subside for example, due to neutralising drug antibodies. Further treatment ...
Nur für Besitzer und Autoren: Kontrollseite des Eintrags
Downloadstatistik